March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance...

18
HIV interventions and performance management: what can we learn from the data? Stefano M Bertozzi Point of Care Diagnostics Seminar Saint Patrick’s Day, 2015

Transcript of March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance...

Page 1: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

HIV interventions and performance management: what can we learn from the data?

Stefano M Bertozzi

Point of Care Diagnostics Seminar

Saint Patrick’s Day, 2015

Page 2: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Evaluación de la eficiencia técnica de los programas

de prevención y tratamiento de VIH

Sergio Bautista, Director, Economía de la Salud

Page 3: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Número de sitios que componen la muestra analítica, por tipo de unidad y país

Hospital de referencia

Hospital general

Centro de salud

Otras unidades primarias

Total

HTC

Kenya 2 20 15 11 48

Rwanda - 1 51 - 52

South Africa 2 22 11 20 55

Zambia - 14 42 5 61

PMTCT

Kenya 2 17 14 6 39

Rwanda - 1 51 - 52

South Africa 1 10 12 20 43

Zambia - 13 35 1 49

VMMC

Kenya 1 12 14 10 37

Rwanda - 7 20 - 27

South Africa 1 17 4 5 27

Page 4: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Costo por cliente de HTC, PMTCT y cascada de atención

HTC PMTCT

17 453 5 1,367 27 154 21 142 61 1,207 2,441 16 3,641 3,923 114 574 1,978 70 767 3,887

$10

$100

$1,000

Kenya Rwanda South Africa Zambia Kenya Rwanda South Africa Zambia

Ave

rag

e c

ost

pe

r clie

nt

(US

D)

Type of client Tested Tested + positive Positive + on ART

Kenya Rwanda South Africa Zambia

6.2

15

8.6

2.91.4 .7

1921

24

13

19

12

0

5

10

15

20

25

NationalHIV prevalence

HTC positivityrate

PMTCT positivityrate

NationalHIV prevalence

HTC positivityrate

PMTCT positivityrate

NationalHIV prevalence

HTC positivityrate

PMTCT positivityrate

NationalHIV prevalence

HTC positivityrate

PMTCT positivityrate

HIV

pre

vale

nce

(%

)

Note: Labels inside the bars indicate precise dollar figures

Note: Positivity rate was calculated as the percentage of (HTC , PMTCT) clients tested and HIV+ / (HTC , PMTCT) clients tested

Page 5: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Categorías de costos y distribución del personal

Page 6: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Tanzania: Number of People Living with HIV, 2014

Page 7: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

1

10

42

07

31

04

13

51

66

19

72

28

25

92

81

03

11

13

4

12

37

13

40

14

43

15

46

16

49

17

52

18

55

19

58

20

61

21

64

22

67

23

70

24

73

25

76

26

79

27

82

28

85

29

88

30

91

31

94

32

97

34

00

35

03

36

06

37

09

38

12

39

15

40

18

41

21

42

24

43

27

44

30

45

33

46

36

47

39

% H

IV p

osi

tive

wo

me

n id

en

tifi

ed

in 6

mo

nth

s

# sites

Kenya PMTCT Site Yield Distribution (SAPR14)

90% of patients are in 28% of the sites

Geographic Refocusing in Kenya% HIV Positive Women Identified in PMTCT Sites

Page 8: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Costos promedio y escala

Page 9: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Excess costs: viral supp. & immun. recovery vs treatment costs

Baseline CD4>200 cel/mm3 VL<50 copies/mm3 (6−18 m)VL<50 copies/mm3 (6−18 m)

and CD4 recovery (>400cel/mm3)

$10,000

$20,000

$30,000

$40,000

$50,000

25 50 75 25 50 75 25 50 75Percentage of clients, by clinical characteristic

Ave

rag

e a

nnual co

st p

er

clie

nt

with

VL<

50

and

CD

4>

400

(U

SD

)

New clients2012

200

400

600

Page 10: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Percentage of patients who initiatedART with CD4>200 cel/ml

0% 25% 50% 75% 100%Percentage of patients withCV<50 copies/ml (6−18 m)

0% 25% 50% 75% 100%Percentage of patients with CV<50 copies/ml

and CD4 recovery

0% 25% 50% 75% 100%

Notes: Bar widths are propor tional to patient volume

Programa de atención en México: desempeño clínico a nivel de la unidad

Page 11: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data
Page 12: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

IN THE LAST YEAR

To improve management, need to monitor

Page 13: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data
Page 14: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data
Page 15: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data
Page 16: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Reaching 100% ART coverage for TB/HIV patients must be a priority

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%A

ngo

la

Bo

tsw

a…

Cam

ero

Co

te…

DR

Eth

iop

ia

Gh

ana

Hai

ti

Ken

ya

Leso

tho

Mal

awi

Mo

zam

Nam

ibia

Nig

eria

Rw

and

a

Sou

th…

Swaz

ila…

Tan

zan

ia

Uga

nd

a

Zam

bia

Zim

bab

* ART eligibility at <350 CD4

World Health Organization, Global TB report 2013

Goal: 100% Coverage

Current ART coverage among eligible* TB PLHIV

Page 17: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

Agradecimientos

- El proyecto ORPHEA es financiado por la Fundación Bill & Melinda Gates.

- Agradecemos la colaboración de nuestros socios académicos en Kenya, Rwanda, Sudáfrica, Zambia y los Estados Unidos.

- Estamos agradecidos con nuestros colegas del Programa Global de VIH/SIDA del Banco Mundial, el CGD y ONUSIDA por su apoyo y colaboración.

Page 18: March 17 2015 PoCDx Seminar - Stefano Bertozzi - HIV Prevention Interventions & Performance Management: What Can We Learn From the Data

……………………………………………………………………………

PEPFAR

Ambassador Deborah L. Birx, M.D.U.S. Global AIDS Coordinator

U.S. Department of State

UCSF

October, 2014

Changing the Course of the HIV/AIDS EpidemicUsing Data, Modeling, Economic Analyses and Innovation

to Improve Program Impact